A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features.

Trial Profile

A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University: ECOG1808).
    • 22 Nov 2012 New source identified and integrated (Mayo Clinic; NCT01164228).
    • 11 Jul 2012 Planned end date changed from 1 Sep 2011 to 1 Jun 2021 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top